Navigation Links
Iomai Announces Year-End 2007 Financial Results and Business Progress
Date:3/6/2008

not replicate results seen in previous trials; Iomai may not obtain the financing necessary to advance its programs; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Quarterly Report on Form 10-Q for the three months ended September 30, 2007, and filed with the Securities and Exchange Commission. Whether any approved product would be self-administered would depend on many factors, including the outcome of any additional studies the Company conducts evaluating self-administration and the views of regulatory agencies. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read the Company's filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.

STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

Year ended December 31,

2007 2006

Revenues $10,667 $1,475

Cost and expenses:

Research and development 31,605 28,041

General and administrative 8,172 5,857

Total costs and expenses 39,777 33,898

Loss from operations (29,110) (32,423)

Other income (expense)
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
2. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
3. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
4. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
5. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
6. Dragon announces new product launch; increase in annual production output capacity
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. China Yingxia International Announces Q4 and FY 2007 Estimates
9. Bristol-Myers Squibb Announces Dividend
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
11. Maxygen Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... build Yondelis(R) sales network across Western Europe, ... a services agreement with PharmaMar, a subsidiary of ... oncology sales team in Western,Europe to promote Yondelis(R), ... the marketing authorization, will be,responsible for marketing the ...
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ... discovery, development and commercialization of,novel small molecule ... Stolz, Ph.D., to the position of Vice ... be responsible for overseeing the,company,s partnering and ...
... the tiny structures look like fragments of nanoscopic pearl ... are linked together by means of a special fullerene-binding ... nanopearls in the latest issue of the journal Angewandte ... 60 carbon atoms whose linkages resemble the five- and ...
Cached Biology Technology:Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 2Innovex to Promote PharmaMar's Yondelis(R) Cancer Treatment 3Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development 2Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development 3
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... Embryonic stem cells with identical genomes grow into distinctive ... time, scientists believed the differences among cell types arose ... cells. Then, studies showed that adult neurons uniquely lack ... the rest of the body's cells. , Now, it ...
... is a database with the necessary infrastructure ... functional genomic data and protocols for an emerging ... the water-flea, Daphnia's ecological merit is unequaled among ... freshwater ecosystems and over 200 years of biological ...
... extinction in Earth history some 251 million years ago was ... was followed by a delayed recovery that lasted for millions ... suggests that a sharp decline in atmospheric oxygen levels was ... and the very slow recovery. , Earth's land at the ...
Cached Biology News:Gene keeps neural cells on correct developmental path 2Gene keeps neural cells on correct developmental path 3Low oxygen likely made Great Dying worse, greatly delayed recovery 2Low oxygen likely made Great Dying worse, greatly delayed recovery 3
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
Complement factor B (human)...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... 10 Capillary Electrophoresis Running Buffer was designed ... throughput demands of todays sequencing labs. As ... TBE to the gel-based sequencing community Sigma ... capacity to meet your buffer needs. Scientists ...
Biology Products: